Gore Hybrid Vascular Graft earns CE Mark

WL Gore and Associates (Gore) has announced that its award-winning Gore Hybrid Vascular Graft has been granted European CE Mark approval.

The device has been available in the US since 2010 and has been proven to expand treatment options for optimal outflow by maximising the number of access sites available.

Designed as a vascular prosthesis for replacement or bypass of diseased vessels impacted by aortic aneurysmal, peripheral vascular and end-stage renal disease, it is able to address common causes of graft failure, such as intimal hyperplasia, thrombosis and seroma.

More than 2,500 successful implants for dialysis access and other vascular procedures have taken place since the product's US debut.

Chuck Biggerstaff, associate with the Gore venous access business, said: "Receiving CE Mark for the Gore Hybrid Vascular Graft demonstrates our commitment to providing physicians with innovative technology that can expand treatment options and improve patient outcomes worldwide."

This comes after the company was presented with a gold prize at the 2012 Medical Design Excellence Awards for the device last month.